Easton Pharmaceuticals Announces That Easton and Its JV Partner, Alliance Group, Have Generated $40,000 in Revenues in the First Week of Operations
June 11, 2018 10:24 ET
|
Easton Pharmaceuticals Inc.
Operations are Anticipated to Continually Increase, Which Includes Volume and Pricing, While it Prepares to Launch Its More Profitable Aggregate Operations TORONTO, ON, June 11, 2018 (GLOBE...
Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors
October 22, 2015 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral...
IMAP's Healthcare Industry Global Report Forecasts Move to Emerging Markets
April 01, 2011 13:40 ET
|
IMAP, Inc.
SARASOTA, FL--(Marketwire - April 1, 2011) - IMAP, Inc., an exclusive global merger and acquisition (M&A) organization, announced the findings of its Healthcare Industry Global Report 2011 at its...
Oxygen Biotherapeutics Reports Second Quarter FY2011 Financial Results
December 09, 2010 18:00 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich...
Threshold Pharmaceuticals Announces Clinical Development Results for Cancer Candidate TH-302
November 12, 2009 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 12, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation related to Threshold's clinical stage hypoxia-activated prodrug,...
Cyclacel Pharmaceuticals to Present at BIO Investor Forum
October 21, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Oct. 21, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that its President and Chief Executive Officer Spiro Rombotis will...
ImaRx Therapeutics Reports Fourth Quarter and Year Ended 2008 Financial Results
March 06, 2009 18:00 ET
|
ImaRx Therapeutics, Inc.
REDMOND, Wash., March 6, 2009 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a biopharmaceutical company focused on the development of new treatments for vascular disorders leveraging its...
Meda: Interim Report, January -- September 2005
November 07, 2005 11:24 ET
|
Meda
STOCKHOLM, Sweden, Nov. 7, 2005 (PRIMEZONE) -- Interim report, January -- September 2005:
-- Group sales amounted to SEK 1614 million (570 million)
-- Operating profit increased to SEK 361.3...
Taro Receives Approval For Mupirocin Ointment USP, 2% ANDA
September 23, 2005 12:50 ET
|
Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., Sept. 23, 2005 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. has received approval from the U.S. Food and...
Angstrom Pharmaceuticals Announces that A6 in Combination with Tamoxifen Decreases Breast Tumor Growth and Metastasis in vivo
August 15, 2002 09:01 ET
|
Angstrom Pharmaceuticals
SAN DIEGO, Aug. 15, 2002 (PRIMEZONE) -- Scientists from McGill University and Angstrom Pharmaceuticals Inc., (San Diego, CA) published preclinical results on the combination therapy of its drug A6...